NIEHS Funds Six-Member Toxicogenomics Consortium

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

RESEARCH TRIANGLE, North Carolina-Five academic research centers will join the National Institute of Environmental Health Sciences (NIEHS) to form a consortium to study how genes interact with the environment to cause cancer and other

RESEARCH TRIANGLE, North Carolina—Five academic research centers will join the National Institute of Environmental Health Sciences (NIEHS) to form a consortium to study how genes interact with the environment to cause cancer and other diseases, an emerging field known as toxicogenomics. Each of the groups in the 5-year, $37 million program funded by the NIEHS will receive grants totaling more than $7 million.

The consortium will work with NIEHS scientists and use genomics to determine how disease occurs, identify potential environmental hazards, predict potential disease, identify exposed individuals, and prevent disease. The consortium members and their projects are as follows:

NIEHS: gene expression profiling to explore environmental stresses on human health. This research group will make use of gene expression microarray technology validation studies.

University of North Carolina at Chapel Hill: the study of susceptibility factors in the genomic response to toxicants.

Fred Hutchinson Cancer Research Center: gene expression profiling in transgenic mice and rats, and in human cell lines exposed to environmentally relevant agents.

Oregon Health and Science University: cell-specific injury in the central nervous system and gene profiling of induction mechanisms associated with neurotoxicant exposures.

Duke University: gene expression profiling to explore environmental stresses on human health.

Massachusetts Institute of Technology: gene expression profiling to explore environmental alkylating agents stresses on human health. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video